Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2022-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：2021年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report for the year 2021" from Shanghai Sairen Biotechnology Co., Ltd. It details the independent directors' professional backgrounds, attendance at meetings, duties performed, and their evaluation of the company's governance and operations during the year 2021. The content focuses on the independent directors' activities and their compliance with legal and governance requirements, rather than presenting financial statements or audit results. This type of document is a report on board/management information, specifically about independent directors' duties and evaluations. It is not an annual report, audit report, or any other financial report. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it is a substantive report, not just an announcement or certification, so it is not RPA or RNS.
2022-04-29 Chinese
赛伦生物：独立董事关于第三届董事会第七次会议相关事项的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors providing their prior approval opinion regarding the proposal to reappoint the audit firm for the 2022 fiscal year. It references auditing standards and the audit firm's qualifications but does not contain any financial statements or audit results itself. The document is short (619 characters) and serves as an internal governance or procedural approval related to audit matters, not the audit report itself. Therefore, it fits best under 'Audit Report / Information (AR)' as it relates to audit matters but is not a full annual report or audit report document. Confidence is high due to clear references to audit firm reappointment and audit standards. FY 2022
2022-04-29 Chinese
赛伦生物：独立董事关于第三届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several proposals to be submitted to the 2021 annual shareholders' meeting, including profit distribution, auditor appointment, director and supervisor remuneration, and insurance for directors and officers. It references compliance with company law, securities law, listing rules, and company articles. The document is a formal opinion related to board meeting resolutions and the upcoming annual general meeting, but it is not the annual report itself, nor is it a voting result announcement. It is a governance-related document expressing independent directors' opinions on board matters to be presented at the AGM. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or voting result announcement either.
2022-04-29 Chinese
赛伦生物：《内幕信息知情人登记管理制度》（2022年4月）
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System' for Shanghai SAILUN Biotechnology Co., Ltd. It details the company's internal policies and procedures for managing insider information, including definitions, responsibilities, confidentiality, registration, and legal compliance. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shanghai Stock Exchange. The document is a governance and compliance manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, earnings data, or shareholder voting results. It is a detailed internal governance document about insider information management and confidentiality obligations. Therefore, the most appropriate classification is Governance Information (CGR). The document length (8504 characters) and content support this classification with high confidence.
2022-04-29 Chinese
赛伦生物：2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes signatures from company officers and auditors, and detailed financial tables for the fiscal year 2021. The presence of extensive financial data, management discussion, and audit opinions confirms this is the official yearly report covering company activity and full financial performance for 2021. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-29 Chinese
赛伦生物：2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 年年度报告摘要" which translates to "2021 Annual Report Summary". It contains detailed financial data for the year 2021, including total assets, net profit, revenue, and quarterly breakdowns. It also includes extensive business descriptions, industry analysis, risk factors, shareholder information, and management discussion. The length of the document (12,757 characters) and the depth of financial and operational data indicate this is the actual annual report content, not just an announcement or summary notice. There is no indication that this is a certification, proxy, or other regulatory filing. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.